2010
DOI: 10.1038/clpt.2009.234
|View full text |Cite
|
Sign up to set email alerts
|

A Model-Based Approach to Dose Selection in Early Pediatric Development

Abstract: The establishment of a rationale for determining dosing regimens in pediatric patients remains a challenge in drug development. In this investigation, we explored several methodologies to support bridging studies and evaluated the best descriptor of developmental changes that can be used as a covariate for dose adjustment in children. The proposed approach is illustrated for the antiviral drug abacavir. Using data from six pharmacokinetic studies in adults and one study in children, a model-based analysis was … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
74
0

Year Published

2010
2010
2023
2023

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 56 publications
(75 citation statements)
references
References 16 publications
(18 reference statements)
1
74
0
Order By: Relevance
“…Given the mechanism of action of abacavir, the exposure-effect relationship can be assumed to be independent of age. The adult AUC0-12 target value of 6.02 mg h ml -1 can be set as the target exposure for effective and safe treatment in children [10]. These findings provide the rationale for AUC guided abacavir dosing adjustment, but implementation in clinical practice is missing.…”
Section: Introductionmentioning
confidence: 99%
“…Given the mechanism of action of abacavir, the exposure-effect relationship can be assumed to be independent of age. The adult AUC0-12 target value of 6.02 mg h ml -1 can be set as the target exposure for effective and safe treatment in children [10]. These findings provide the rationale for AUC guided abacavir dosing adjustment, but implementation in clinical practice is missing.…”
Section: Introductionmentioning
confidence: 99%
“…Despite the potential of innovative research methods in collecting data on drug effects in children and/or developing clinical trials, it seems that their benefits as tools in pharmaceutical R&D has remained undervalued and sometimes ignored by key stakeholders (Cella et al, 2010;Abernethy & Burckart,2010). This attitude appears to contradict those ethical and scientific beliefs that emphasize the need for evaluation of the risk-benefit ratio in special populations, such as the paediatric one.…”
Section: Research Aim and Results (What Have We Done)mentioning
confidence: 99%
“…Pediatric developmental changes must be taken into account, as they also play a key role in pharmacokinetics. For example, obvious maturation changes are related to the volume increase of luminal fluids, intestinal surface area, and intestinal permeability (12)(13)(14)(15). Administered dose is also fundamentally important, and therefore, there may be a need for a more quantitative, dose-dependent approach to pediatric BCS (16,17).…”
Section: Challenges In the Development Of Pediatric Dosage Forms Frommentioning
confidence: 99%